[go: up one dir, main page]

KR960705780A - 평활근 이완제로서의 디아미노사이클로부텐-3.4-디온(Diaminocyclobutene-3.4-diones as smooth muscle relaxants) - Google Patents

평활근 이완제로서의 디아미노사이클로부텐-3.4-디온(Diaminocyclobutene-3.4-diones as smooth muscle relaxants) Download PDF

Info

Publication number
KR960705780A
KR960705780A KR1019960702542A KR19960702542A KR960705780A KR 960705780 A KR960705780 A KR 960705780A KR 1019960702542 A KR1019960702542 A KR 1019960702542A KR 19960702542 A KR19960702542 A KR 19960702542A KR 960705780 A KR960705780 A KR 960705780A
Authority
KR
South Korea
Prior art keywords
cyclobut
ylamino
dione
ene
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1019960702542A
Other languages
English (en)
Inventor
안토니 부테라 죤
아담 앤테인 슈일러
Original Assignee
이곤 이. 버그
아메리칸 홈 프로덕츠 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이곤 이. 버그, 아메리칸 홈 프로덕츠 코포레이션 filed Critical 이곤 이. 버그
Publication of KR960705780A publication Critical patent/KR960705780A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/43—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pens And Brushes (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)

Abstract

일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염은 평활근 이완제이다.
상기 식에서, R1및 R2는 독립적으로 수소, 직쇄 또는 측쇄 알킬이거나, 모노- 또는 비-사이클릭 알킬이고, A는 알킬, 퍼플루오로알킬, 알콕시, 퍼플루오로알콕시, 아미노, 알킬아미노, 디알킬아미노, 알킬설폰아미도, 알킬카복스아미도, 니트로, 시아노 또는 카복실에 의해 치환될 수 있는 N-헤테로사이클이거나, A는 시아노, 니트로, 알킬, 퍼플루오로알킬, 알콕시, 퍼플루오로알콕시, 아미노, 알킬아미노, 디알킬아미노, 설파밀, 알킬설폰아미도, 아릴카복스아미도, 알킬설포닐, 퍼플루오로알킬설포닐, 아릴설포닐, 클로로, 브로모, 플루오로, 요오도, 1-이미다졸릴 또는 카복실 중에서 선택된 1 또는 2개의 치환제를 함유하는 치환된 페닐 그룹이다.

Description

평활근 이완제로서의 디아미노사이클로부텐-3.4-디온(Diaminocyclobutene-3.4-diones as smooth muscle relaxants)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염.
    상기 식에서, R1및 R2는 서로 독립적으로 수소, C1-10직쇄 알킬, C1-10측쇄 알킬 또는 C3-10사이클릭 또는 비사이클릭이 알킬이고, A는
    로 이루어진 그룹(여기서, R3은 수소, C1-6알킬, C1-6퍼플루오로알킬, C1-6알콕시, C1-6퍼플루오로알콕시, 아미노, C1-6알킬아미노, C2-12디알킬아미노, C1-6알킬설폰아미도, C2-7알킬카복스아미도, 니트로, 시아노, 또는 카복실이다)으로부터 선택되거나, A는 일반식의 치환된 페닐 그룹(여기서, R4및 R5는 서로 독립적으로 시아노, 니트로, 아미노, C1-6알킬, C1-6퍼플루오로알킬, C1-6알콕시, C1-6퍼플루오로알콕시, 아미노, C1-6알킬아미노, C2-12디알킬아미노, 설파밀, C1-6알킬설폰아미도, C6-12알킬설폰아미도, C2-7알킬카복스아미도, C7-13아릴카복스아미도, C1-6알킬설포닐, C1-6퍼플루오로알킬설포닐, C6-12아릴설포닐, 클로로, 브로모, 플루오로, 요오도, 1-이미다졸릴, 카복실 및 수소로 이루어진 그룹으로부터 선택되고, 단, R4및 R5는 동시에 수소일 수 없다)이다.
  2. 제1항에 있어서, A가
    로 이루어진 그룹으로부터 선택되거나, A가 일반식의 치환된 페닐 그룹(여기서, R4및 R5는 서로 독립적으로 시아노, 니트로, 아미노, 클로로, 브로모, 플루오로, 요오도, 1-이미다졸릴, 카복실 또는 수소로 이루어진 그룹으로부터 선택되고, 단 R4및 R5는 동시에 수소일 수 없다)인 화합물 또는 이의 약제학적으로 허용되는 염.
  3. 제1항에 있어서, A가
    로 이루어진 그룹으로부터 선택되거나, A가 일반식의 치환된 페닐 그룹(여기서, R4및 R5는 서로 독립적으로 시아노, 니트로, 아미노, 클로로, 브로모, 플루오로, 요오도, 1-이미다졸릴, 카복실 및 수소로 이루어진 그룹으로부터 선택되고, 단 R4및 R5는 동시에 수소일 수 없다)인 화합물 또는 이의 약제학적으로 허용되는 염.
  4. 알킬 그룹의 탄소수가 1 내지 6이고 페닐 그룹이 1 또는 2개의 시아노, 니트로, 아미노, 할로 또는 카복실 그룹에 의해 치환된 3-알킬아미노-4-[(치환된 페닐)아미노]-사이클로부트-3-엔-1,2-디온.
  5. 제1항에 있어서, 3-(피라딘-4-일아미노)-4-(1,2,2-트리메틸-프로필아미노)-사이클로부트-3-엔-1,2-디온; (엑소)-3-(비사이클로[2.2.1]헵트-2-일아미노)-4-(피리딘-4-일아미노)-4-사이클로부트-3-엔-1,2-디온; 3-(피리딘-3-일아미노)-4-(1,2,2-트리메틸-프로필아미노)-사이클로부트-3-엔-1,2-디온; 3-(2-메틸에틸아미노)-4-(피리딘-3-일아미노)(사이클로부트-3-엔-1,2-디온; 3-디메틸아미노-4-(피리딘-3-일아미노)-사이클로부트-3-엔-1,2-디온; 3-아미노-4-(피리딘-3-일아미노)-사이클로부트-3-엔-1,2-디온 또는 3-3급-부틸아미노-4-(피리딘-3-일아미노)-사이클로부트-3-엔-1,2-디온인 화합물.
  6. 제1항에 있어서, 3-3급-부틸아미노-4-(이소퀴놀린-5-일아미노)- 사이클로부트-3-엔-1,2-디온; 3-아미노-4-(이소퀴놀린-5-일아미노)-사이클로부트-3-엔-1,2-디온; 3-(퀴놀린-8-일아미노)-4-(1,2,2-트리메틸-프로필아미노)-사이클로부트-3-엔-1,2-디온; 3-메틸아미노-4-(퀴놀린-8-일아미노)-사이클로부트-3-엔-1,2-디온; 3-아미노-4-(퀴놀린-8-일아미노)-사이클로부트-3-엔-1,2-디온; 3-(퀴놀린-3-일아미노)-4-(1,2,2-트리메틸-프로필아미노)-사이클로부트-3-엔-1,2-디온; 3-3급-부틸아미노-4-(퀴놀린-3-일아미노)-사이클로부트-3-엔-1,2-디온; 3-(퀴놀린-3-일아미노)-4-(1,1-디메틸-프로필아미노)-사이클로부트-3-엔-1,2-디온; 3-(6-메톡시-퀴놀린-8-일아미노)-4-(1,2,2-트리메틸-프로필아미노)-사이클로부트-3-엔-1,2-디온; 3-(6-메톡시-퀴놀린-8-일아미노)-4-메틸아미노-사이클로부트-3-엔-1,2-디온; 3-3급-부틸아미노-4-(퀴놀린-6-일아미노)-사이클로부트-3-엔-1,2-디온 또는 3-(이소퀴놀린-5-일아미노)-4-메틸아미노-사이클로부트-3-엔-1,2-디온인 화합물.
  7. 제1항에 있어서, 3-3급-부틸아미노-4-(1H-인다졸-6-일아미노)-사이클로부트-3-엔-1,2-디온; (엑소)-4-[2-(비사이클로[2.2.1]헵트-2-일아미노)-3, 4-디옥소-사이클로부트-1-에닐아미노]-벤조니트릴; 또는 4-[3,4-디옥소-2-(1,2,2-트리메틸-프로필아미노)-사이클로부트-1-에닐아미노]-벤젠설폰아미드인 화합물.
  8. 제1항에 있어서, 4-[3,4-디옥소-2-(1,2,2-트리메틸-프로필아미노)-사이클로부트-1-에닐아미노]-벤조니트릴인 화합물.
  9. 제1항에 있어서, (+)-(R)-4-[3,4-디옥소-2-(1,2,2-트리메틸-프로필아미노)-사이클로부트-1-에닐아미노]-3-에틸-벤조니트릴인 화합물.
  10. 제1항에 있어서, (+)-(R)-4-[3,4-디옥소-2-(1,2,2-트리메틸-프로필아미노)-사이클로부트-1-에닐아미노]-3-메톡시-벤조니트릴인 화합물.
  11. 평활근 수축 역효과 저하를 필요로 하는 환자에게 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염을 경구 또는 비경구적으로 투여함을 포함하여, 평활근 수축 역효과를 저하시키는 방법.
    상기 식에서, R1및 R2는 서로 독립적으로 수소, C1-10직쇄 알킬, C1-10측쇄 알킬 또는 C3-10사이클릭 또는 비사이클릭 알킬이고, A는
    로 이루어진 그룹(여기서, R3은 수소, C1-6알킬, C1-6퍼플루오로알킬, C1-6알콕시, C1-6퍼플루오로알콕시, 아미노, C1-6알킬아미노, C2-12디알킬아미노, C1-6알킬설폰아미도, C2-7알킬카복스아미도, 니트로, 시아노, 또는 카복실이다)으로부터 선택되거나, A는 일반식의 치환된 페닐 그룹(여기서, R4및 R5는 서로 독립적으로 시아노, 니트로, 아미노, C1-6알킬, C1-6퍼플루오로알킬, C1-6알콕시, C1-6퍼플루오로알콕시, 아미노, C1-6알킬아미노, C2-12디알킬아미노, 설파밀, C1-6설폰아미도, C6-12알킬설폰아미도, C2-7알킬카복스아미도, C7-13아릴카복스아미도, C1-6알킬설포닐, C1-6퍼플루오로알킬설포닐, C6-12아릴설포닐, 클로로, 브로모, 플루오로, 요오도, 1-이미다졸릴, 카복실 및 수소로 이루어진 그룹으로부터 선택되고, 단, R4및 R5는 동시에 수소일 수 없다)이다.
  12. 제10항에 있어서, 평활근 역 수축이 요실금을 야기시키는 방법.
  13. 제10항에 있어서, 평활근 역 수축이 과민성 장 증후군을 야기시키는 방법.
  14. 약제학적으로 허용되는 담체와의 배합물로 또는 약제학적으로 허용되는 담체와 함께 제1항 내지 제8항중의 어느 한 항에 따르는 화합물을 포함하는 약제학적 조성물.
  15. 일반식(Ⅱa)의 화합물을 일반식(Ⅳ)의 화합물과 반응시키고, 경우에 따라 A1을 A로 전환시키거나, Ra1을 R1으로 전환시키거나 Ra2를 R2로 전환시키고, 경우에 따라, 일반식(Ⅰ)의 화합물을 이의 약제학적으로 허용되는 염으로 전환시키거나, 일반식(Ⅰ)의 화합물의 염을 일반식(Ⅰ)의 화합물을 전환시킴을 포함하여 제1항에 따르는 화합물을 제조하는 방법.
    상기 식에서, A1은 제1항에서 정의한 A이거나, 이로 전환될 수 있는 원자의 그룹이고, X는 이탈 그룹이며, Ra1및 Ra2는 각각 제1항에서 정의한 R1및 R2이거나, 이로 전환될 수 있는 원자의 그룹이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960702542A 1993-11-17 1994-11-01 평활근 이완제로서의 디아미노사이클로부텐-3.4-디온(Diaminocyclobutene-3.4-diones as smooth muscle relaxants) Abandoned KR960705780A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/153,706 1993-11-17
US08/153,706 US5354763A (en) 1993-11-17 1993-11-17 Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
PCT/US1994/012561 WO1995014005A1 (en) 1993-11-17 1994-11-01 Diaminocyclobutene-3,4-diones as smooth muscle relaxants

Publications (1)

Publication Number Publication Date
KR960705780A true KR960705780A (ko) 1996-11-08

Family

ID=22548391

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960702542A Abandoned KR960705780A (ko) 1993-11-17 1994-11-01 평활근 이완제로서의 디아미노사이클로부텐-3.4-디온(Diaminocyclobutene-3.4-diones as smooth muscle relaxants)

Country Status (21)

Country Link
US (5) US5354763A (ko)
EP (1) EP0729457B1 (ko)
JP (1) JPH09505296A (ko)
KR (1) KR960705780A (ko)
AT (1) ATE174907T1 (ko)
AU (1) AU677479B2 (ko)
CA (1) CA2175386A1 (ko)
DE (1) DE69415554T2 (ko)
DK (1) DK0729457T3 (ko)
ES (1) ES2126241T3 (ko)
FI (1) FI962070A0 (ko)
GR (1) GR3029646T3 (ko)
HU (1) HU215603B (ko)
IL (1) IL111529A (ko)
LV (1) LV12258B (ko)
NZ (1) NZ276568A (ko)
PH (1) PH31054A (ko)
SG (1) SG47587A1 (ko)
SI (1) SI0729457T1 (ko)
WO (1) WO1995014005A1 (ko)
ZA (1) ZA948877B (ko)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466712A (en) * 1994-11-04 1995-11-14 American Home Products Corporation Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
US5464867A (en) * 1994-11-16 1995-11-07 American Home Products Corporation Diaminocyclobutene-3,4-diones
DK0796243T3 (da) * 1994-11-16 1999-09-13 American Home Prod Diaminocyclobuten-3,4-dioner
IL127261A0 (en) * 1996-06-17 1999-09-22 American Home Prod Heterocyclylmethylamino derivatives of cyclobutene-3,4- diones as potassium channel modulators
US5872139A (en) * 1996-06-17 1999-02-16 American Home Products Corporation Heterocyclymethylamino derivatives of cyclobutene-3,4-diones
US5763474A (en) * 1996-07-17 1998-06-09 American Home Products Corporation Substituted N-arylmethylamino derivatives of cyclobutene-3,4-diones
US5750574A (en) * 1996-07-17 1998-05-12 American Home Products Corporation Fluorinated N-arylmethylamino derivatives of cyclobutene-3,4-diones
US5846999A (en) * 1996-07-17 1998-12-08 American Home Products Corporation Substituted N-arylmethylamino derivatives of cyclobutene-3,4-diones
US5780505A (en) * 1996-07-17 1998-07-14 American Home Products Corporation Substituted N-arylmethylamino derivatives of cyclobutene-3, 4-diones
US5840764A (en) * 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
AU6250298A (en) * 1997-01-30 1998-08-25 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US6376555B1 (en) 1998-12-04 2002-04-23 American Home Products Corporation 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers
WO2000034230A1 (en) * 1998-12-04 2000-06-15 American Home Products Corporation 4-3-substituted-amino-cyclobut-3-ene-1,2-diones and use for influencing smooth muscle contraction
AU6019900A (en) * 1999-11-24 2001-06-04 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine crystals and process for producing the same
US20030204085A1 (en) * 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
US6495576B2 (en) 2001-02-07 2002-12-17 Abbott Laboratories Aminal diones as potassium channel openers
KR20100008794A (ko) * 2001-04-16 2010-01-26 쉐링 코포레이션 Ｃｘｃ-케모카인 수용체 리간드로서의 3,4-이치환된 사이클로부텐-1,2-디온
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) * 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
CA2462862A1 (en) * 2001-10-12 2003-04-17 Schering Corporation 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists
US6878709B2 (en) * 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
CN100444839C (zh) * 2002-03-18 2008-12-24 先灵公司 式(i)化合物在制备治疗化学激活物中介的疾病的药物中的应用
WO2004033440A1 (en) * 2002-10-09 2004-04-22 Schering Corporation Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands
CA2550189A1 (en) * 2003-12-19 2005-07-21 Schering Corporation Thiadiazoles as cxc- and cc- chemokine receptor ligands
MXPA06007205A (es) * 2003-12-22 2006-08-31 Schering Corp Dioxidos de isotiazol como ligandos del receptor cxc y cc-quimiocina.
ES2327840T3 (es) 2004-12-23 2009-11-04 Gpc Biotech Ag Derivados de acido escuarico con actividad antiproliferativa.
EP1912971A2 (en) * 2005-06-29 2008-04-23 Shering Corporation Di-substituted oxadiazoles as cxc-chemokine receptor ligands
MX2008000367A (es) * 2005-06-29 2008-03-07 Schering Corp Oxidiazolopirazinas y tiadiazolopirazinas 5,6-di-sustituidas como ligandos de receptor de quimiocina en la que dos cisternas son separadas por un solo aminoacido.
EP2021316A1 (en) * 2006-05-26 2009-02-11 Abbott Laboratories Inhibitors of polo-like kinases
JP2009542700A (ja) * 2006-07-07 2009-12-03 シェーリング コーポレイション Ｃｘｃケモカイン受容体リガンドとしての３，４−ジ置換シクロブテン−１，２−ジオン
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
AU2009264273B2 (en) 2008-06-24 2015-01-22 Onxeo Dk, Branch Of Onxeo S.A., France Squaric acid derivatives as inhibitors of the nicotinamide
UA103198C2 (en) * 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
US9874158B2 (en) 2009-09-04 2018-01-23 Lg Fuel Cell Systems, Inc Engine systems and methods of operating an engine
US9178235B2 (en) 2009-09-04 2015-11-03 Lg Fuel Cell Systems, Inc. Reducing gas generators and methods for generating a reducing gas
US8668752B2 (en) * 2009-09-04 2014-03-11 Rolls-Royce Fuel Cell Systems (Us) Inc. Apparatus for generating a gas which may be used for startup and shutdown of a fuel cell
US9140220B2 (en) 2011-06-30 2015-09-22 Lg Fuel Cell Systems Inc. Engine systems and methods of operating an engine
US9083020B2 (en) 2009-09-04 2015-07-14 Lg Fuel Cell Systems Inc. Reducing gas generators and methods for generating reducing gas
US8597841B2 (en) 2009-09-04 2013-12-03 Lg Fuel Cell Systems Inc. Method for generating a gas which may be used for startup and shutdown of a fuel cell
US9118048B2 (en) 2009-09-04 2015-08-25 Lg Fuel Cell Systems Inc. Engine systems and methods of operating an engine
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
AU2018318075B2 (en) 2017-08-14 2023-04-13 Allergan, Inc. 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof
MX2021003318A (es) 2018-09-21 2021-05-14 Pfizer Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas utiles como inhibidores de ccr6.
CN116947756B (zh) * 2023-08-02 2025-02-07 中国药科大学 环丁烯二酮基喹啉类化合物及其制备方法、药物组合物和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390701A (en) * 1981-05-18 1983-06-28 Bristol-Myers Company 1-Amino-2-[3-(3-piperidinomethylphenoxy)propylamino]cyclobutene-3,4-dione
JPS60255756A (ja) * 1984-06-01 1985-12-17 Ikeda Mohandou:Kk アミノアルキルフエノキシ誘導体
US5011837A (en) * 1988-08-09 1991-04-30 E. R. Squibb & Sons, Inc. Aryl cyanoguanidines: potassium channel activators and method of making same
ES2088895T3 (es) * 1988-09-16 1996-10-01 Beecham Group Plc Derivados de benzopirano con actividad antihipertensora.
GB8924373D0 (en) * 1989-10-30 1989-12-20 Beecham Group Plc Novel compounds
US5212283A (en) * 1992-03-03 1993-05-18 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polyimides containing the cyclobutene-3, 4-dione moiety
JPH0692915A (ja) * 1992-07-28 1994-04-05 Sumitomo Metal Ind Ltd １，２−ジアミノシクロブテン−３，４−ジオン誘導体及びその用途

Also Published As

Publication number Publication date
ZA948877B (en) 1996-05-09
JPH09505296A (ja) 1997-05-27
US5403854A (en) 1995-04-04
FI962070A7 (fi) 1996-05-15
DK0729457T3 (da) 1999-08-23
GR3029646T3 (en) 1999-06-30
ATE174907T1 (de) 1999-01-15
IL111529A (en) 1999-08-17
US5403853A (en) 1995-04-04
AU1086695A (en) 1995-06-06
NZ276568A (en) 1996-11-26
HU9601310D0 (en) 1996-07-29
HK1011353A1 (en) 1999-07-09
FI962070L (fi) 1996-05-15
FI962070A0 (fi) 1996-05-15
SG47587A1 (en) 1998-04-17
HUT75655A (en) 1997-05-28
EP0729457A1 (en) 1996-09-04
WO1995014005A1 (en) 1995-05-26
US5397790A (en) 1995-03-14
HU215603B (hu) 1999-01-28
SI0729457T1 (en) 1999-04-30
US5354763A (en) 1994-10-11
DE69415554T2 (de) 1999-05-12
DE69415554D1 (de) 1999-02-04
IL111529A0 (en) 1995-01-24
LV12258B (en) 1999-09-20
US5401753A (en) 1995-03-28
AU677479B2 (en) 1997-04-24
LV12258A (lv) 1999-04-20
ES2126241T3 (es) 1999-03-16
CA2175386A1 (en) 1995-05-26
PH31054A (en) 1998-02-03
EP0729457B1 (en) 1998-12-23

Similar Documents

Publication Publication Date Title
KR960705780A (ko) 평활근 이완제로서의 디아미노사이클로부텐-3.4-디온(Diaminocyclobutene-3.4-diones as smooth muscle relaxants)
KR970707096A (ko) 평활근 이완 활성을 갖는 N-아릴 및 N-헤테로아릴-1,2-디아미노사이클로부텐-3,4-디온(N-Aryl and N-heteroaryl-1,2-diaminocyclobutene-3,4-diones with smooth muscle relaxing activities)
AU5501496A (en) Benzimidazole compounds and their use as modulators of the g abaa receptor complex
BR9611618A (pt) Composto processo para sua preparação composição farmacêutica e utilização de um compostos
BR9508608A (pt) Composto formulação farmacêutica e processo para prevenir ou tratar arritmia
BR0317109A (pt) Composição de graxa de uréia, e, métodos de lubrificação de um suporte, e de uma superfìcie deslizante
CA2309296A1 (fr) Composition cosmetique comprenant un compose de type indigoide
US4167625A (en) Trans-4,5,13,14-tetradehydro-PGI1 amides
KR850003719A (ko) 시아노피라졸 제초제에 대한 개량
DK0711291T3 (da) N-(Piperidinyl-1-alkyl)-substituerede cyclohexancarboxylsyreamider som 5-HT1A-receptorantagonister
KR970707081A (ko) 디아미노사이클로부텐-3, 4-디온(Diaminocyclobutene-3, 4-diones)
CA2209422A1 (en) 4-amino-3-acylnaphthyridine derivatives
KR940005529A (ko) 사이클로헥산 유도체 및 이를 함유하는 액정 조성물
DE69402935D1 (de) Substituierte arylalkylaminobenzyl-aminopropanamide, ihre herstellung und verwendung als antiepileptische, neuroprotektive und antidepressive mittel
ES469314A1 (es) Procedimiento para la preparacion de acido ciclohexanocarbo-xilico
ES8204715A1 (es) Un procedimiento para preparar 2-amino-3-benzoil-fenilaceta-midas y homologos ciclicos
ES477878A1 (es) Un procedimiento para preparar mercaptoacilaminoacidos sustituidos con halogeno.
TW334337B (en) Preparation and composition for a compound of controlling and preventing phytopathogenic fungi
IE882107L (en) Pyrimidones
KR960010649A (ko) 이중환상 옥사졸 및 티아졸 치환된 에테르
KR920012026A (ko) 2-아릴-2-치환-5-(트리플루오로메틸)피롤 화합물의 제조방법
KR870006045A (ko) 8α-아실아미노에르고린의 제법 및 그 약학 조성물
ES8800663A1 (es) Procedimiento para preparar compuestos arilsulfonicos.
KR960000853A (ko) 치환된 페닐-4[(e)-알크-2-에노일옥시] 벤조에이트
IE790152L (en) Benzodioxans

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19960515

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19991101

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20010823

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20020219

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee